Onco-Innovations Provides Information Regarding Inka Health's USPTO Provisional Patent Application for AI-Powered Precision Medicine Platform, SynoGraph
Onco-Innovations (OTCQB:ONNVF) announced that its subsidiary, Inka Health, filed a provisional patent application with the USPTO for SynoGraph, its next-generation AI platform, on January 28, 2025. The application, titled 'Method and System for Causal Graph Generation and Analysis,' aims to protect their AI-driven precision medicine approach.
SynoGraph utilizes AI-powered causal inference to identify cancer patients likely to respond to specific treatments. The platform integrates various medical data types including genomics, transcriptomics, and proteomics to uncover insights for treatment decisions and clinical trial design. The technology is expected to enhance Onco's drug research initiatives by potentially streamlining trial design and patient selection, which could reduce development costs and improve patient outcomes.
Onco-Innovations (OTCQB:ONNVF) ha annunciato che la sua sussidiaria, Inka Health, ha presentato una domanda di brevetto provvisorio presso l'USPTO per SynoGraph, la sua piattaforma AI di nuova generazione, il 28 gennaio 2025. La domanda, intitolata 'Metodo e Sistema per la Generazione e Analisi di Grafi Causali', mira a proteggere il loro approccio di medicina di precisione guidato dall'AI.
SynoGraph utilizza inferenze causali potenziate dall'AI per identificare i pazienti oncologici che potrebbero rispondere a trattamenti specifici. La piattaforma integra vari tipi di dati medici, tra cui genomica, trascrittomica e proteomica, per scoprire informazioni utili per le decisioni terapeutiche e la progettazione di studi clinici. La tecnologia dovrebbe migliorare le iniziative di ricerca farmacologica di Onco, semplificando potenzialmente la progettazione degli studi e la selezione dei pazienti, il che potrebbe ridurre i costi di sviluppo e migliorare i risultati per i pazienti.
Onco-Innovations (OTCQB:ONNVF) anunció que su subsidiaria, Inka Health, presentó una solicitud de patente provisional ante la USPTO para SynoGraph, su plataforma de IA de próxima generación, el 28 de enero de 2025. La solicitud, titulada 'Método y Sistema para la Generación y Análisis de Grafos Causales', tiene como objetivo proteger su enfoque de medicina de precisión impulsado por IA.
SynoGraph utiliza inferencia causal impulsada por IA para identificar a los pacientes con cáncer que probablemente responderán a tratamientos específicos. La plataforma integra varios tipos de datos médicos, incluidos genómica, transcriptómica y proteómica, para descubrir información útil para decisiones de tratamiento y diseño de ensayos clínicos. Se espera que la tecnología mejore las iniciativas de investigación farmacéutica de Onco al simplificar potencialmente el diseño de ensayos y la selección de pacientes, lo que podría reducir los costos de desarrollo y mejorar los resultados para los pacientes.
Onco-Innovations (OTCQB:ONNVF)는 그 자회사인 Inka Health가 2025년 1월 28일에 차세대 AI 플랫폼 SynoGraph에 대해 USPTO에 임시 특허 출원을 했다고 발표했습니다. 이 출원은 '인과 그래프 생성 및 분석을 위한 방법 및 시스템'이라는 제목으로, AI 기반의 정밀 의료 접근 방식을 보호하는 것을 목표로 하고 있습니다.
SynoGraph는 AI 기반 인과 추론을 활용하여 특정 치료에 반응할 가능성이 있는 암 환자를 식별합니다. 이 플랫폼은 유전체학, 전사체학 및 단백질체학을 포함한 다양한 의료 데이터 유형을 통합하여 치료 결정 및 임상 시험 설계를 위한 통찰력을 발견합니다. 이 기술은 잠재적으로 시험 설계 및 환자 선택을 간소화하여 Onco의 약물 연구 이니셔티브를 향상시키고 개발 비용을 줄이며 환자 결과를 개선할 것으로 기대됩니다.
Onco-Innovations (OTCQB:ONNVF) a annoncé que sa filiale, Inka Health, a déposé une demande de brevet provisoire auprès de l'USPTO pour SynoGraph, sa plateforme d'IA de nouvelle génération, le 28 janvier 2025. La demande, intitulée 'Méthode et Système pour la Génération et l'Analyse de Graphes Causals', vise à protéger leur approche de médecine de précision basée sur l'IA.
SynoGraph utilise l'inférence causale alimentée par l'IA pour identifier les patients atteints de cancer susceptibles de répondre à des traitements spécifiques. La plateforme intègre divers types de données médicales, y compris la génomique, la transcriptomique et la protéomique, pour découvrir des informations utiles pour les décisions de traitement et la conception d'essais cliniques. La technologie devrait améliorer les initiatives de recherche pharmaceutique d'Onco en rationalisant potentiellement la conception des essais et la sélection des patients, ce qui pourrait réduire les coûts de développement et améliorer les résultats pour les patients.
Onco-Innovations (OTCQB:ONNVF) gab bekannt, dass ihre Tochtergesellschaft, Inka Health, am 28. Januar 2025 einen vorläufigen Patentantrag beim USPTO für SynoGraph, ihre KI-Plattform der nächsten Generation, eingereicht hat. Der Antrag mit dem Titel 'Methode und System zur Erzeugung und Analyse von Kausalgraphen' zielt darauf ab, ihren KI-gesteuerten Ansatz für präzisionsmedizinische Anwendungen zu schützen.
SynoGraph nutzt KI-gestützte kausale Inferenz, um Krebspatienten zu identifizieren, die wahrscheinlich auf bestimmte Behandlungen ansprechen. Die Plattform integriert verschiedene medizinische Datentypen, einschließlich Genomik, Transkriptomik und Proteomik, um Erkenntnisse für Behandlungsentscheidungen und das Design klinischer Studien zu gewinnen. Die Technologie wird voraussichtlich die Forschungsinitiativen von Onco im Bereich der Arzneimittelforschung verbessern, indem sie potenziell das Studiendesign und die Patientenauswahl optimiert, was die Entwicklungskosten senken und die Patientenergebnisse verbessern könnte.
- Filed USPTO provisional patent application for AI platform SynoGraph
- Technology potentially reduces clinical trial timelines and development costs
- Platform could enhance drug research and development capabilities
- None.
VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health ("Inka"), filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for its next-generation AI platform, SynoGraph. The patent application, titled, "Method and System for Causal Graph Generation and Analysis", was filed on January 28, 2025, and marks an important step in protecting Onco's innovative approach to AI-driven precision medicine and oncology drug development.
SynoGraph leverages AI-powered causal inference to identify which cancer patients may be most likely to respond to specific treatments, which has the potential to advance precision medicine. By integrating diverse multimodal medical data-including genomics, transcriptomics, and proteomics-SynoGraph aims to uncover previously hidden insights that can potentially optimize treatment decisions and clinical trial design. This proprietary technology is expected to enhance Onco's ability to move forward on its drug research and development initiatives.
As a cornerstone of Onco's subsidiary Inka Health's AI-powered drug development platform, SynoGraph has the potential to offer an AI-enabled framework through which to structure and integrate complex real-world clinical data for drug research, development and trial optimization. By streamlining trial design and patient selection, SynoGraph has the potential to shorten clinical trial timelines-a crucial factor in reducing development costs and improving patient outcomes.
"Filing this provisional patent application is an important step in safeguarding our proprietary AI technology, aimed at ensuring that SynoGraph remains a protected and valuable asset in AI-driven drug development. Protecting our innovation is essential as we continue to push the boundaries of AI-driven precision medicine, strengthening our position in the healthcare technology sector and opening doors for strategic collaborations and commercialization opportunities," said Dr. Paul Arora, CEO of Inka Health.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of SynoGraph, and the Company's other research initiatives, and the prospects of the Company, including its ability to safeguard its technologies, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize SynoGraph or any of the Company's other technologies, the failure to receive a patent or to otherwise safeguard the Company's intellectual property rights, the failure to successfully complete further trials and studies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
When did Inka Health file the USPTO patent application for SynoGraph (ONNVF)?
What is the purpose of Onco-Innovations' SynoGraph AI platform (ONNVF)?
How does SynoGraph technology benefit ONNVF's drug development process?
What types of medical data does ONNVF's SynoGraph platform analyze?
